Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo

Noble, F.A.C. le; Hekking, Johan W.M.; Straaten, H. W. M. van; Slaaf, Dick W.; Boudier, H. A. J. Struyker

doi:10.1016/0014-2999(91)90552-2

Cited by 168 publications

(101 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It may also have a role in neovascularization. Recent studies have shown ATII-dependent stimulation of angiogenesis in experimental models (Fernandez et al, 1985;Le Noble et al, 1991;1993) and enhanced vessel density in muscle tissue (Hemandez et al, 1992). Captopril has been shown previously to be an effective inhibitor of angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma

Hii

Nicol²,

Gotley³

et al. 1998

Br J Cancer

123

View full text Add to dashboard Cite

Summary The effect of captopril on tumour growth was examined in a xenograft model of human renal cell carcinoma (RCC). Inoculation of the human RCC cell line SN12K-1 (106 cells) under the left kidney capsule of severe combined immunodeficient (SCID) mice resulted in the growth of large tumours, with an increase in weight of the inoculated kidney of 3.69 ± 1.63-fold (mean ± s.d.) when compared with the contralateral normal kidney. In mice treated with captopril (19 mg kg-1 day-' or 94 mg kg-1 day-1 administered in the drinking water), there was a significant dose-related reduction in tumour development; the tumour bearing kidneys weighed 1.9 ± 0.42 and 1.55 ± 0.42 times the normal kidneys, respectively (P < 0.05 compared with untreated animals). In vitro, captopril at clinically achievable doses (0.1-10 ,UM) had no significant effect on the incorporation of [3H]thymidine into SN12K-1 cells. Thus, this highly significant attenuation by captopril of in vivo tumour growth does not appear to be due to a direct effect on the proliferation of the tumour cells. Further studies are required to determine the mechanism of inhibition of tumour growth by captopril, in particular to evaluate the role of angiotensin 11 in this process.

show abstract

Section: Discussionmentioning

confidence: 99%

Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma

Hii

Nicol²,

Gotley³

et al. 1998

Br J Cancer

123

View full text Add to dashboard Cite

show abstract

“…Besides the well-known effects on vascular tonus, several studies implicate a role of local RAS in oxidative stress defence [33,34] and in the regulation of angiogenesis [35][36][37][38]. To evaluate the effect of islet RAS on the formation of a new islet vascular system after transplantation, losartan was, in some cases, added to the drinking water of newly transplanted animals.…”

Section: Discussionmentioning

confidence: 99%

Angiotensin II type 1 receptor inhibition markedly improves the blood perfusion, oxygen tension and first phase of glucose-stimulated insulin secretion in revascularised syngeneic mouse islet grafts

et al. 2005

View full text Add to dashboard Cite

Aims/hypothesis: We recently found evidence of an angiotensin-generating system in pancreatic islets. The present study investigated the effect of endogenously produced angiotensin II on microcirculation and function in transplanted islets. Materials and methods: Losartan, an angiotensin II type 1 receptor inhibitor, was administered either acute intravenously to mice with 4-week-old islet renal subcapsular transplants, or added to the drinking water for the final 14 days or throughout the 4-week post-transplantation period. The graft-bearing kidney was, in some cases, dissected out and perfused in vitro to evaluate the effect of angiotensin II and losartan on glucose-stimulated insulin release from the grafts. Results: Losartan treatment throughout the 4-week post-transplantation period had negative effects on islet revascularisation as well as on islet graft insulin release. However, administration of losartan, either intravenously or orally, after the formation of a new vascular network, improved islet graft blood perfusion. P O2 in the islet transplants was also effectively improved by the losartan treatment. Graft perfusion experiments showed a markedly better first phase of glucose-stimulated insulin release in transplanted islets when exposed to losartan. In contrast, acute administration of angiotensin II decreased islet graft blood flow, PO 2 and glucose-stimulated insulin release. Conclusions/interpretation: This study shows that inhibition of the islet reninangiotensin system may be a feasible strategy to increase the blood perfusion, PO 2 and function within islet grafts. Such treatment should not be initiated, however, before the islet vascular system has been formed.

show abstract

“…Angiotensin II (ANG II) has pro-angiogenic effects in various situations such as sponge implant models of angiogenesis, 34 chick chorioallantoic membrane, 35 rat cremaster muscle, 19 rat carotid artery, 36 and cornea. 37 There is evidence that the AT1 receptor mediates the proliferative effects of ANG II 7,19,38 however, the role of the AT2 receptor in these processes is less well understood with reports of pro-, anti-, and no effects on cell growth and angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

Retinal Angiogenesis Is Mediated by an Interaction between the Angiotensin Type 2 Receptor, VEGF, and Angiopoietin

Sarlos

Rizkalla

Moravski

et al. 2003

The American Journal of Pathology

131

View full text Add to dashboard Cite

There is evidence that angiotensin II, vascular endothelial growth factor (VEGF), angiopoietins, and their cognate receptors participate in retinal angiogenesis. We investigated whether angiotensin type 2-receptor blockade (AT2-RB) reduces retinal angiogenesis and alters the expression of VEGF/VEGF-R2 and angiopoietin-Tie2. Retinopathy of prematurity (ROP) was induced in Sprague Dawley (SD) rats by exposure to 80% oxygen from postnatal (P) days 0 to 11, followed by 7 days in room air. ROP shams were in room air from P0 -18. A group of ROP rats received the AT2-RB, PD123319, by mini-osmotic pump (5 mg/kg/day) from P11-18 (angiogenesis period). Evaluation of the retinal status of the AT2 receptor indicated that this receptor, as assessed by real-time PCR, immunohistochemistry, and in vitro autoradiography, was present in the retina, was more abundant than the AT1 receptor in the neonatal retina, and was increased in the ROP model. AT2-RB reduced retinal angiogenesis. VEGF and VEGF-R2 mRNA were increased in ROP and localized to blood vessels, ganglion cells, and the inner nuclear layer, and were decreased by PD123319. Angiopoietin2 and Tie2, but not angiopoietin1 mRNA were increased with ROP, and angiopoietin2 was reduced with PD123319. This study has identified a potential retinoprotective role for AT2-RB possibly mediated via interactions with VEGF-and angiopoietin-dependent pathways.

show abstract

Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo

Cited by 168 publications

References 8 publications

Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma

Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma

Angiotensin II type 1 receptor inhibition markedly improves the blood perfusion, oxygen tension and first phase of glucose-stimulated insulin secretion in revascularised syngeneic mouse islet grafts

Retinal Angiogenesis Is Mediated by an Interaction between the Angiotensin Type 2 Receptor, VEGF, and Angiopoietin

Contact Info

Product

Resources

About